EGFR tyrosine kinase inhibitors (TKIs), as single-target inhibitors of EGFR, have completely changed the treatment model for patients with non-small cell lung cancer (NSCLC) [9, 10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.